Safety profile of anti-CD19 CAR T-cell therapy axicabtagene ciloleucel - 101793

Spotlight
Video

Safety profile of anti-CD19 CAR T-cell therapy axicabtagene ciloleucel

VJHemOnc has 1608 videos Subscribe Here

Loading........
Description: A major concern surrounding novel therapeutics is their safety, which must be characterized thoroughly. Here, Sattva Neelapu, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the safety data regarding the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel; KTE-C19) from the long-term follow-up of the ZUMA-1 trial (NCT02348216). Dr Neelapu covers what the most common adverse events were, when they occurred and their reversibility. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Shared By : VJHemOnc
Posted on : 01/05/18
Added : 12 months ago
Category : Lymphoma